A landmark strategic collaboration has been announced between CelliPont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Ronawk, the innovative developer of the Bio-OS™ biological operating system.
This partnership, unveiled on November 19, 2025, is set to tackle some of the most significant hurdles in regenerative medicine by accelerating the scalable, high-quality expansion of mesenchymal stem cells (MSCs).
Tackling the Primary Bottleneck in Regenerative Medicine
Mesenchymal stem cells are a cornerstone of modern therapeutic research, widely recognized for their powerful regenerative and immunomodulatory properties.
However, their full clinical potential has been hampered by a critical bottleneck: the inability to manufacture them at a large scale in a manner that is consistent, cost-effective, and therapeutically viable.
This manufacturing challenge has remained a significant limiting factor for the broad clinical adoption of MSC-based therapies.
A Powerful Synergy: Combining Manufacturing Expertise with Platform Innovation
This new alliance creates a powerful synergy by merging Cellipont’s deep expertise in current Good Manufacturing Practice (cGMP) and process development with Ronawk’s groundbreaking Bio-OS™ platform.
By recreating the natural microenvironment of cells, the integrated solution aims to dramatically improve the quality, reproducibility, and efficiency of MSC production, paving the way for the next generation of advanced biologics.
“Cellipont is committed to enabling the next generation of cell therapies,” stated Darren Head, CEO of Cellipont Bioservices. “Integrating Ronawk’s Bio-OS™ platform into our manufacturing capabilities allows us to overcome bottlenecks in MSC expansion and deliver scalable, consistent, and cost-effective therapeutic products to our partners and, ultimately, to patients.”
Introducing the Bio-OS™: A New Paradigm for Cell Cultivation
Ronawk’s Bio-OS™ represents a fundamental shift in biomanufacturing. Unlike legacy technologies designed for microbes, which tend to exhaust mammalian cells, the Bio-OS™ is built from the ground up specifically for the cells required for advanced therapies. It cultivates cells in an environment that mimics the human body, resulting in healthier, more potent outputs at a fraction of the cost and physical footprint of existing systems.
“Expanding MSCs at scale while preserving quality, viability, and potency has long been a challenge in regenerative medicine,” said A.J. Mellott, Ph.D., CEO of Ronawk. “By partnering with Cellipont, we’re combining advanced process know-how with innovative platform technology to deliver higher-quality cells for use across biologics, exosome therapeutics, and regenerative medicine.”
The Future of Scalable Cell Therapies
The collaboration between Cellipont Bioservices and Ronawk promises to close the critical manufacturing gap that has constrained the field.
By offering a clear pathway to scalable, high-quality MSC production, this partnership is poised to accelerate therapeutic development across the entire biotech landscape and bring life-changing treatments to patients more quickly and efficiently.
About Cellipont Bioservices
Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. To learn more, visit www.cellipont.com.
About Ronawk
At Ronawk, we are building a biological operating system (Bio-OS™) that acts as a compass for mammalian biology. Instead of burning cells out, Ronawk’s Bio-OS cultivates them in environments that mimic the body. This yields healthier, more potent outputs at a fraction of the cost and footprint of current systems. Find out more at ronawk.com.
